IV PPI Shortage Plan
Due to a recent critical national shortage of IV proton pump inhibitors (PPI) secondary to increased demand, an emergency shortage plan was formulated and implemented to circumvent the critical shortage. The shortage plan, which is currently implemented, includes an active CPOE alert asking prescribers to consider PO PPI therapy, IV push famotidine therapy, or IV famotidine infusion as alternatives. In lieu of a pantoprazole infusion, prescribers are asked to consider the following dosing regimen for IV famotidine where clinically appropriate:

<table>
<thead>
<tr>
<th>Dosage Regimen</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Famotidine 20 mg IV push bolus, followed by famotidine continuous infusion 40 mg/24 hours (1.7 mg/hr)</td>
<td></td>
</tr>
</tbody>
</table>

Amikacin Lab Alert Update
Due to the recent annual lab alert review, our system will be implementing changes to our current lab alert values, which are called to prescribers, as well as our institution therapeutic ranges to help enhance monitoring of amikacin to improve patient care and outcomes.

<table>
<thead>
<tr>
<th>Previous 2014 Lab Levels</th>
<th>New 2015 Lab Levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alert (called to prescribers)</td>
<td>Trough</td>
</tr>
<tr>
<td>&lt; 10 mcg/ml</td>
<td>&gt; 75 mcg/ml (adults)</td>
</tr>
<tr>
<td>&gt; 30 mcg/ml (peds)</td>
<td></td>
</tr>
<tr>
<td>Therapeutic Ranges</td>
<td>Trough</td>
</tr>
<tr>
<td>&lt; 8 mcg/ml</td>
<td>15-30 mcg/ml</td>
</tr>
</tbody>
</table>

Peak range refers to “traditional dosing” peak levels not to be drawn with “extended interval” aminoglycosides

Asmanex (mometasone) Therapeutic Interchange and Dulera Formulary Addition Update on Implementation
Due to a recent class review showing comparable efficacy and safety, coupled with cost savings, we will be removing Flovent (fluticasone) inhaler and adding Asmanex 220 mcg Twisthaler (mometasone) to the adult formulary as the preferred inhaled corticosteroid. Orders for inhaled corticosteroids will be therapeutically interchanged to Asmanex Twisthaler beginning on May 12. A table for this interchange will be available on MOLLI under drug information, then therapeutic interchange. In addition, as part of this review previously approved by P&T, Dulera (mometasone/formoterol), will also be added to the adult formulary effective May 12.
Medication Clinical Decision Support Alerts
In an effort to enhance hospital performance regarding national standards of safety, quality, and efficiency, our hospital will be implementing changes to our computerized provider order entry (CPOE) process. The following recommendations were approved by the P&T Committee:

- Implement dose range checking and therapeutic duplication checking alerts for providers and nurses at point of medication order entry.
- Investigate and implement filtering mechanisms to limit interruptions due to less significant and non-actionable alerts.
- Return to Pharmacy & Therapeutics with recommended filtering mechanisms for final approval.
- Begin deployment as a pilot with alerts to pharmacists only for an initial review period. Solicit feedback from the pharmacists and customize the content (where appropriate) to further reduce insignificant alerts.
- Fully implement alerts to Medical and Nursing staff by end of May of this year.

Formulary Reviews
- Viekira Pack- Not added to the adult formulary.
- Hydrocodone/acetaminophen 10 mg/300 mg oral liquid- Automatic interchange by pharmacists to hydrocodone/acetaminophen 7.5 mg/325 mg oral liquid approved

Approved Order Sets/Power Plans
The following order sets/Powerplans were reviewed and approved:

- New: CRITCARE Epoprostenol FLOLAN Inhalation Plan, CARD Cath Lab Pulm HTN Vasodilator Challenge Plan

Medication Use Evaluations
- Initial Diabetic Ketoacidosis (DKA) Treatment in the Emergency Department- Results noted high rates of adverse events, such as hypoglycemia and hypokalemia, related to treatment of DKA seen across our adult hospital system, which may be improved via adherence to American Diabetes Association treatment algorithms. We will reexamine this data again once the pilot DKA protocol implementation at South is completed before implementing a pilot health-system wide DKA protocol to optimize treatment.
- Use of Sleep Agents in Adult Hospitals at MLH- Results noted that adherence to the sleep agents interchange was high across the system. No trends in patient falls were seen regarding the timing of sleep agent administration and the interchange has not resulted in additional requirements of a second nightly dose. Therefore, we should continue to adhere to the current sleep agent interchange policy.

Drug Shortage Report:
The IV Fluid and Irrigation Solution Shortages continue. Look for updates posted on the home page of Methodist MD. In addition, Compazine injection was added to the shortage list.